{"product_id":"tlis-vrio-analysis","title":"Talis Biomedical Corporation (TLIS): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Talis Biomedical Corporation (TLIS)'s market dominance (or potential pitfalls) starts here: this VRIO analysis rigorously tests its core assets against the pillars of Value, Rarity, Inimitability, and Organization, distilling the findings into the critical summary found in \u0026amp;O4\u0026amp;. Don't just guess at its competitive strength - read on below to see the definitive strategic assessment that shapes Talis Biomedical Corporation (TLIS)'s future success.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTalis Biomedical Corporation (TLIS) - VRIO Analysis: Talis One Sample-to-Answer Platform Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eYou are looking at the core technology of Talis Biomedical Corporation (TLIS), the Talis One system, to see if it offers a durable edge. Honestly, for a company that has recently pivoted its focus and is evaluating strategic alternatives, understanding the strength of its underlying tech is defintely the right place to start.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Rapid, Accurate Point-of-Care Molecular Testing\u003c\/h3\u003e\n\u003cp\u003eThe Talis One platform is designed to deliver central laboratory-level accuracy right where the patient is - at the point-of-care. This means bypassing the time lag of sending samples to a centralized lab, which is crucial for infectious disease management. The system combines a compact instrument, single-use cartridges, and cloud software to provide a true sample-to-answer experience for molecular diagnostics. The potential market opportunity for their targeted women's health and sexually transmitted infection (STI) diagnostics was estimated to be around $5.5 billion in the US back in 2020, showing the scale of the value proposition if they can commercialize it successfully. As of late 2025, the company reports TTM earnings of $0.3 Million USD, which shows the technology is not yet driving significant top-line revenue, but the potential value remains high based on the unmet need it addresses.\u003c\/p\u003e\n\u003cp\u003eThe platform’s value proposition centers on:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRapid turnaround for clinical decisions.\u003c\/li\u003e\n\u003cli\u003eMolecular accuracy at the point-of-care.\u003c\/li\u003e\n\u003cli\u003eDesigned for operation by untrained users.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity: Proprietary Amplification and Automation\u003c\/h3\u003e\n\u003cp\u003eWhat makes the Talis One system stand out is the combination of its proprietary isothermal nucleic acid amplification - a way to copy DNA\/RNA without the high heat cycles of PCR - with full automation packed into a small instrument. This specific integration of chemistry and engineering isn't something you see every day in the point-of-care space. While other companies have NAAT (nucleic acid amplification test) technology, Talis’s specific architecture is what they claim sets it apart. It’s rare to find this level of molecular sophistication miniaturized and automated for distributed settings.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High Barrier Due to IP and Engineering\u003c\/h3\u003e\n\u003cp\u003eThe complexity here suggests imitability is high, meaning it would be tough for a competitor to copy quickly. The core chemistry and the intricate engineering required to integrate it into a reliable, compact, and automated instrument are significant hurdles. This technology is protected by intellectual property, which acts as a moat, at least on paper. Building a comparable system requires deep expertise across molecular biology, microfluidics, and instrument design. It’s not just about having the chemistry; it’s about making it work seamlessly in a cartridge and instrument that a non-lab professional can use reliably.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Focused on New Pipeline After Pivot\u003c\/h3\u003e\n\u003cp\u003eOrganization refers to whether the company is structured to capture the value from its resources. Talis Biomedical has definitely made clear, decisive actions to preserve cash, including significant workforce reductions. The organization has pivoted away from its initial, broader COVID-19 focus to center its efforts on the sexual health pipeline, specifically the Chlamydia\/Gonorrhea\/Trichomonas (CT\/NG\/TV) and other women’s health panels. The fact that they extended their cash runway into 2025 (as reported in early 2023) suggests a disciplined approach to managing resources during this transition phase. However, the ongoing evaluation of strategic alternatives indicates that organizational alignment is still in flux, seeking the best path forward to commercialize this tech.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary, Contingent on Adoption\u003c\/h3\u003e\n\u003cp\u003eThe current competitive advantage is best described as \u003cstrong\u003etemporary\u003c\/strong\u003e. The technology itself has the potential for a sustained advantage due to its rarity and difficulty to imitate. But potential is not realized value. The advantage hinges entirely on achieving successful regulatory clearance - like the 510(k) submissions for their panels - and then achieving meaningful commercial adoption in those new target markets. If they secure clearance and market penetration, the advantage becomes much stronger; until then, it’s a race against time and cash burn.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick look at how the VRIO elements stack up for the Talis One platform:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eKey Data Point\/Observation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eEnables molecular accuracy at point-of-care; potential $5.5B US market for targeted panels.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eProprietary isothermal NAAT combined with full automation in a compact instrument.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\/Costly\u003c\/td\u003e\n\u003ctd\u003eHigh complexity in integrated chemistry and engineering, protected by IP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate\/Evolving\u003c\/td\u003e\n\u003ctd\u003eFocused on sexual health pipeline; cash preservation measures in place; evaluating strategic alternatives.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eDependent on achieving regulatory clearance and successful commercial adoption post-pivot.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the execution risk; the technology is only as good as the next FDA submission date. Finance: draft a 13-week cash view by Friday, factoring in the current operational burn rate post-RIF.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTalis Biomedical Corporation (TLIS) - VRIO Analysis: Core Intellectual Property Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eCore Intellectual Property Portfolio\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eProtects the unique hardware, software, and assay chemistry, creating a barrier against direct replication of the Talis One system. The technology includes an isothermal Nucleic Acid Amplification Test (NAAT) targeting two physically separated locations in the SARS-CoV-2 genome for high sensitivity and inclusivity in the COVID-19 test cartridge.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate; many diagnostics firms have IP, but the specific patents covering the integrated sample prep and isothermal amplification are unique. As of August 14, 2024, the company had 79 Patent Families, with 25 granted patents. Specific granted patents, such as US Patent Number 11633736 (granted April 25, 2023), cover apparatuses like the optical reaction well for assay devices.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eDifficult; patent protection is strong, but competitors could design around claims or develop superior non-patented methods. The company acknowledges that several aspects of its patent portfolio are in much earlier stages of prosecution in the United States and foreign countries. The company incurred $3.1 million in non-recurring expenses in Q1 2023 to obtain a license to patents and cartridge raw materials following a supply agreement termination.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh; the company has historically protected its IP across key jurisdictions (US, EU, China, Japan). The company's commitment to R\u0026amp;D is evidenced by reported Research and Development Expenses of $113.0 million for the twelve months ended December 31, 2022.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained; as long as key patents remain in force, this provides a legal moat around the core technology. The estimated total potential annualized addressable market opportunity for COVID-19 tests in the United States alone was estimated to exceed $7.0 billion.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Financial and Intellectual Property Metrics\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric Category\u003c\/td\u003e\n\u003ctd\u003eMetric Detail\u003c\/td\u003e\n\u003ctd\u003eValue\/Amount\u003c\/td\u003e\n\u003ctd\u003eDate\/Period Reference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntellectual Property\u003c\/td\u003e\n\u003ctd\u003eTotal Patent Families\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e79\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of August 14, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntellectual Property\u003c\/td\u003e\n\u003ctd\u003eGranted Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of August 14, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$113.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTwelve months ended December 31, 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Q1)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13,796 K\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst Quarter 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial\u003c\/td\u003e\n\u003ctd\u003eUnrestricted Cash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$113.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of March 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial\u003c\/td\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents (Q3 End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$88.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnd of Q3 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket\/Opportunity\u003c\/td\u003e\n\u003ctd\u003eEstimated US COVID-19 TAM\u003c\/td\u003e\n\u003ctd\u003eExceeds \u003cstrong\u003e$7.0 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of June 2020 estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial\u003c\/td\u003e\n\u003ctd\u003eNon-recurring IP\/License Expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncurred in Q1 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's organizational efforts to protect IP include seeking protection across multiple jurisdictions.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eSpecific granted patent example: US Patent Number 10046322 for Reaction well for assay device, filed March 22, 2018.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eSpecific application example: Publication number 20230002826 for POLYNUCLEOTIDES FOR THE AMPLIFICATION AND DETECTION OF HUMAN BETA ACTIN, filed December 1, 2020.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company's accumulated deficit as of December 31, 2022, was $478.0 million.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTalis Biomedical Corporation (TLIS) - VRIO Analysis: Automated Cartridge Manufacturing Infrastructure\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eAutomated Cartridge Manufacturing Infrastructure\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Provides the potential for high-volume, low-cost production of single-use consumables, which drives the razor-and-blade revenue model.\n\u003c\/p\u003e\n\u003cp\u003e\nThe infrastructure is designed to meet anticipated volume commercial needs for the Talis One system.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eManufacturing Line Type\u003c\/th\u003e\n\u003cth\u003eStated Capacity (Units\/Day)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManual R\u0026amp;D Line\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~300\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSemi-Automated Chicago Line\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~2,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFully Automated Lines (Reserved for Scale)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~40,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe company has invested in these assets with the expectation that scaling and automation will drive cost of goods reductions for their tests.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; large-scale medical device manufacturing capacity is available, but Talis’s lines are specifically tooled for their proprietary cartridge.\n\u003c\/p\u003e\n\u003cp\u003e\nThe assets are specifically tooled for the Talis One cartridges.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the physical assets are imitable, but the operational know-how to run them efficiently at scale is not easily copied.\n\u003c\/p\u003e\n\u003cp\u003e\nThe company has focused on developing internal expertise in manufacturing.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low; past struggles with scaling production suggest this capability has not been fully optimized or exploited recently.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nIn Q3 2023, management announced exploration of strategic alternatives and a workforce reduction of approximately \u003cstrong\u003e90%\u003c\/strong\u003e, consolidating operations to a single site in Chicago.\n\u003c\/li\u003e\n\u003cli\u003e\nAs of Q3 2023, cash and cash equivalents were \u003cstrong\u003e$88.0M\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nTrailing Twelve Month Revenue as of June 30, 2024 was \u003cstrong\u003e$300K\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it’s a sunk cost that needs immediate commercial volume to justify its existence.\n\u003c\/p\u003e\n\u003cp\u003e\nAssets deemed to have an alternative future use have been capitalized as property and equipment.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTalis Biomedical Corporation (TLIS) - VRIO Analysis: Cloud-Enabled Data and Software Architecture\n\u003c\/h2\u003e\n\u003cp\u003eThe Talis One system is a sample-to-answer, cloud-enabled molecular diagnostic platform that includes a central cloud database as part of its integrated software component.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The cloud-enabled architecture supports remote instrument management and secure data transmission, critical for payor value propositions through macro-level disease monitoring. The potential annualized market opportunity for COVID-19 point-of-care diagnostic tests in the United States was estimated to exceed \u003cstrong\u003e$7.0 billion\u003c\/strong\u003e. Furthermore, the estimated potential annualized market opportunity in the United States for the planned COVID-Flu Panel and women's health\/sexually transmitted infection diagnostics in the development pipeline was approximately \u003cstrong\u003e$5.5 billion\u003c\/strong\u003e in 2020.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eYear\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated US POC COVID-19 Market Opportunity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$7.0 billion\u003c\/strong\u003e+\u003c\/td\u003e\n\u003ctd\u003eAnnualized Estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated US Pipeline Market Opportunity (COVID-Flu\/Women's Health\/STI)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2020 Estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; cloud connectivity is standard, but integrating it seamlessly with a POC molecular instrument is a specific engineering feat.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can build similar cloud backends, but integrating it with the Talis One instrument is proprietary.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the ongoing work on Talis Aspire and Engage suggests continued investment in the software layer.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this is an expected feature in modern diagnostics, not a long-term differentiator on its own.\u003c\/p\u003e\n\u003cp\u003eThe Talis One system has received U.S. FDA Emergency Use Authorization and a CLIA waiver for its SARS-CoV-2 molecular assay.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe platform is designed to deliver results in under an hour.\u003c\/li\u003e\n\u003cli\u003eThe system is designed to provide central laboratory levels of accuracy and be operated by an untrained user.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTalis Biomedical Corporation (TLIS) - VRIO Analysis: Strategic Focus on Women's and Sexual Health Assays\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrategic Focus on Women's and Sexual Health Assays\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Targets a market segment with strong demand for POC testing where immediate treatment decisions are vital, potentially offering a less crowded initial launch path than COVID-19.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe global Sexually Transmitted Disease (STD) diagnostics market size was valued at \u003cstrong\u003eUSD 109.02 Billion\u003c\/strong\u003e in 2024, projected to reach \u003cstrong\u003eUSD 164.90 Billion\u003c\/strong\u003e by 2033, exhibiting a Compound Annual Growth Rate (CAGR) of \u003cstrong\u003e4.47%\u003c\/strong\u003e from 2025-2033.\u003c\/li\u003e\n\u003cli\u003eThe STD diagnostics market is projected to reach \u003cstrong\u003e$99,431.6 million\u003c\/strong\u003e by 2027 from \u003cstrong\u003e$91,441.5 million\u003c\/strong\u003e in 2022, at a CAGR of \u003cstrong\u003e5.6%\u003c\/strong\u003e during the forecast period.\u003c\/li\u003e\n\u003cli\u003eThe STDs diagnostics market is driven by the growing awareness for early disease diagnosis and a shift in focus from centralized laboratories to decentralized Point-of-Care (POC) testing.\u003c\/li\u003e\n\u003cli\u003eTalis is developing a multiplex test for Chlamydia, Gonorrhea, and Trichomoniasis (CT\/NG\/TV) with a preliminary time to result in less than \u003cstrong\u003e30 minutes\u003c\/strong\u003e on the Talis One® system.\u003c\/li\u003e\n\u003cli\u003ePreliminary Positive Percent Agreement (PPA) for the development-stage CT\/NG\/TV test was \u003cstrong\u003e100%\u003c\/strong\u003e for CT, NG, and TV in neat male urine.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many companies target STI\/Women's Health, but Talis has a specific pipeline (CT\/NG\/TV) underway.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Talis One system is designed to deliver lab quality results in less than \u003cstrong\u003e30 minutes\u003c\/strong\u003e, utilizing proprietary NAAT technology.\u003c\/li\u003e\n\u003cli\u003eThe lysis time for challenging targets on the Talis One system was demonstrated as short as \u003cstrong\u003e4 minutes\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; competitors can pivot, but Talis has an early-mover advantage in applying its specific platform to this menu.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCT\/NG\/TV PPA (Male Urine)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePreliminary performance assessment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTV PPA (Female Vaginal Swabs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePreliminary performance assessment (positive samples only)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime to Result (Target)\u003c\/td\u003e\n\u003ctd\u003eLess than \u003cstrong\u003e30 minutes\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFor CT\/NG\/TV multiplex test on Talis One\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTLIS Shares Outstanding (as of 3\/15\/2023)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e56,730,589\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCommon stock and preferred stock outstanding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this pivot was a decisive strategic action taken to align resources with market need after the COVID-19 setback.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTalis incurred expenses related to Reduction in Force (RIF) events during the year ended December 31, 2022, totaling \u003cstrong\u003e$1.0 million\u003c\/strong\u003e and \u003cstrong\u003e$1.5 million\u003c\/strong\u003e recorded within operating expenses.\u003c\/li\u003e\n\u003cli\u003eThe aggregate market value of common equity held by non-affiliates as of June 30, 2021, was \u003cstrong\u003e$181,704,426\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe aggregate market value of common equity held by non-affiliates as of June 30, 2022, was \u003cstrong\u003e$7,342,048\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this focus is a strategic choice that can be matched by competitors entering the same niche.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNorth America held the largest share of the STD diagnostics market at over \u003cstrong\u003e36.8%\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003cli\u003eThe overall STI incidence has climbed \u003cstrong\u003e58.38%\u003c\/strong\u003e since 1990.\u003c\/li\u003e\n\u003cli\u003eIn 2019, the U.S. recorded \u003cstrong\u003e616,392\u003c\/strong\u003e reports of gonorrhea.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTalis Biomedical Corporation (TLIS) - VRIO Analysis: Leaner Operating Expense Structure (Post-2023 Restructuring)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The massive workforce reduction (approx. \u003cstrong\u003e90%\u003c\/strong\u003e) and consolidation significantly lowered the monthly cash burn rate, extending the runway into \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe restructuring included consolidating operations to a single site in Chicago. The company also reduced its Redwood City, California office and lab space by two-thirds, expecting approximately \u003cstrong\u003e$9 million\u003c\/strong\u003e of cash savings over the life of the lease.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod\/Date\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses\u003c\/td\u003e\n\u003ctd\u003eQ3 2022\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses\u003c\/td\u003e\n\u003ctd\u003eQ3 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operating Activities\u003c\/td\u003e\n\u003ctd\u003eQ1 2022\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operating Activities\u003c\/td\u003e\n\u003ctd\u003eQ1 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnrestricted Cash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$98.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$88.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey financial improvements supporting the leaner structure include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOperating expenses decreased from \u003cstrong\u003e$27.6 million\u003c\/strong\u003e in Q3 2022 to \u003cstrong\u003e$17.1 million\u003c\/strong\u003e in Q3 2023.\u003c\/li\u003e\n\u003cli\u003eNet cash used in operating activities for the first quarter of 2023 was \u003cstrong\u003e$16.5 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$43.8 million\u003c\/strong\u003e in the first quarter of 2022.\u003c\/li\u003e\n\u003cli\u003eA \u003cstrong\u003e62%\u003c\/strong\u003e improvement in net cash used in operating activities year-over-year for Q1 2023.\u003c\/li\u003e\n\u003cli\u003eA \u003cstrong\u003e53%\u003c\/strong\u003e improvement in year-to-date net cash used in operating activities year-over-year as of Q2 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; cost-cutting is a common response to financial pressure, but the scale of the reduction (approx. \u003cstrong\u003e90%\u003c\/strong\u003e workforce cut) is notable.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; competitors can cut costs, but the specific structure and lower burn rate achieved are company-specific, tied to the decision to pause clinical trials and seek strategic alternatives.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the organization is now lean, focused on core R\u0026amp;D and strategic review (evaluation of strategic alternatives), which helps preserve capital.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this is a defensive posture that only buys time; it doesn't generate revenue, as Q3 2023 revenue was only \u003cstrong\u003e$0.1 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTalis Biomedical Corporation (TLIS) - VRIO Analysis: Institutional Investor Base Stability\n\u003c\/h2\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3 style=\"margin-top:0; margin-bottom:0;\"\u003eValue\u003c\/h3\u003e\n\n\u003cp\u003e\nThe presence of institutional investors (holding \u003cstrong\u003e9.06%\u003c\/strong\u003e as of the period May 2025 through October 2025) provides a baseline of external validation and potential future capital support.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth\u003eMetric\u003c\/th\u003e\n      \u003cth\u003eValue\u003c\/th\u003e\n      \u003cth\u003eSource\/Date Context\u003c\/th\u003e\n    \u003c\/tr\u003e\n  \u003c\/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eInstitutional Shareholding Percentage\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e9.06%\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eAs of October 2025 (Trend stable since May 2025)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eMutual Fund Shareholding Percentage\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e0.92%\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eAs of October 2025 (Trend stable since May 2025)\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eNumber of Institutions Filing 13D\/G or 13F\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eLatest SEC Filings Data\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eTotal Shares Held by Filers\u003c\/td\u003e\n      \u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n      \u003ctd\u003eLatest SEC Filings Data\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3 style=\"margin-top:0; margin-bottom:0;\"\u003eRarity\u003c\/h3\u003e\n\n\u003cp\u003e\nLow; most public companies have institutional holders. The low absolute number of filing institutions (\u003cstrong\u003e1\u003c\/strong\u003e) suggests a very narrow institutional base, which is rare, though the percentage holding (\u003cstrong\u003e9.06%\u003c\/strong\u003e) is not exceptionally low for a micro-cap stock.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3 style=\"margin-top:0; margin-bottom:0;\"\u003eImitability\u003c\/h3\u003e\n\n\u003cp\u003e\nHigh; ownership patterns are public record and not something the company controls directly. The specific low share count held by the single filing institution (\u003cstrong\u003e6\u003c\/strong\u003e shares) is a result of market activity, not a controlled resource.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3 style=\"margin-top:0; margin-bottom:0;\"\u003eOrganization\u003c\/h3\u003e\n\n\u003cp\u003e\nModerate; maintaining institutional interest at a \u003cstrong\u003e9.06%\u003c\/strong\u003e level despite operational turbulence shows some confidence in the underlying asset, though the extremely low share count (\u003cstrong\u003e6\u003c\/strong\u003e) held by the sole reporting institution suggests minimal active commitment.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n  \u003cli\u003eAnalyst Coverage: \u003cstrong\u003e4\u003c\/strong\u003e analysts cover Talis Biomedical Corporation.\u003c\/li\u003e\n  \u003cli\u003eMarket Capitalization: \u003cstrong\u003eUS$2.917m\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eStock Exchange: OTC Markets (OTCPK).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3 style=\"margin-top:0; margin-bottom:0;\"\u003eCompetitive Advantage\u003c\/h3\u003e\n\n\u003cp\u003e\nNone; this is a market condition, not a unique resource.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTalis Biomedical Corporation (TLIS) - VRIO Analysis: Talis Aspire\/Engage Software Ecosystem\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e These non-diagnostic software tools offer a potential, albeit minor, alternative revenue stream or a value-add for institutional customers.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; specialized software for legal\/research is common.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; these are established software products with ongoing iterative improvements planned for late \u003cstrong\u003e2025\u003c\/strong\u003e and early 2026.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; active development suggests a dedicated team is maintaining and enhancing this asset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None; it diversifies risk but is not central to the core value proposition.\u003c\/p\u003e\n\n\u003cp\u003eThe context for the software ecosystem's value contribution is framed by the overall corporate financial status. The Trailing Twelve Month (TTM) Revenue for Talis Biomedical Corporation was reported as \u003cstrong\u003e$408.00K\u003c\/strong\u003e as of June 30, 2024, which represents an \u003cstrong\u003e-85.69%\u003c\/strong\u003e year-over-year decline. The company's Net Income for the TTM period ending around the same time was \u003cstrong\u003e-$51.03m\u003c\/strong\u003e, and Free Cash Flow was \u003cstrong\u003e-$40.23m\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eTimeframe\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTM Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$408.00K\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue YoY Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-85.69%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-year decline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$51.03m\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFinancial context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned Software Enhancements\u003c\/td\u003e\n\u003ctd\u003eTagging with library-controlled vocabulary, improved list analytics, list import from PDF\/Word\u003c\/td\u003e\n\u003ctd\u003ePlanned for late \u003cstrong\u003e2025\u003c\/strong\u003e\/early \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTalis Engage Improvement\u003c\/td\u003e\n\u003ctd\u003eAccessibility features\u003c\/td\u003e\n\u003ctd\u003ePlanned for late \u003cstrong\u003e2025\u003c\/strong\u003e\/early \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe active development roadmap confirms the ongoing investment in the software suite, supporting the high organization assessment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEnhancements planned for the 'Add Resource' modal.\u003c\/li\u003e\n\u003cli\u003eNew tagging feature launch anticipated in \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eConfiguration options for Talis Engage were updated in early \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNew data points planned for institutions using Advanced MIS.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTalis Biomedical Corporation (TLIS) - VRIO Analysis: FDA Regulatory Experience (EUA and 510(k) Process)\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe experience navigating the Emergency Use Authorization (EUA) process for COVID-19 and planning subsequent 510(k) filings provides institutional knowledge for future submissions.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate; many firms have EUA experience, but Talis has specific experience with their platform's chemistry.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eDifficult; the specific documentation and interactions are proprietary to Talis.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eModerate; while the COVID-19 plan was paused, the knowledge base remains with key personnel.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary; this experience is only valuable if they successfully re-engage the regulatory pathway for their current pipeline.\u003c\/p\u003e\n\n\u003cp\u003eThe last reported cash balance before the 2025 goal was \u003cstrong\u003e\\$88.0M\u003c\/strong\u003e in Q3 2023, which management aimed to stretch into 2025 with a burn rate around \u003cstrong\u003e\\$4–5M\u003c\/strong\u003e per month. The company's cash and cash equivalents were \u003cstrong\u003e\\$113.0M\u003c\/strong\u003e as of March 31, 2023, and \u003cstrong\u003e\\$98.2M\u003c\/strong\u003e as of June 30, 2023. Operating expenses in Q3 2023 were \u003cstrong\u003e\\$17.1M\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eSensitivity Analysis on Cash Runway based on a \u003cstrong\u003e\\$3.5M\u003c\/strong\u003e burn rate by the end of Q4 2025, starting from the Q3 2023 cash balance:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStarting Cash Balance (End of Q3 2023)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$88.0M\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHypothetical Monthly Burn Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$3.5M\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHypothetical Quarterly Burn Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$10.5M\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime Period (End Q3 2023 to End Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9 Quarters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Burn Over Period\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$94.5M\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Balance (End of Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$(6.5M)\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eRegulatory Pathway Context:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCOVID-19 clinical study paused on July 19, 2023, and subsequently terminated.\u003c\/li\u003e\n\u003cli\u003ePrior plan included submitting COVID-19 510(k) in early 2024.\u003c\/li\u003e\n\u003cli\u003ePrior plan included securing regulatory clearance for three test panels by the end of 2025.\u003c\/li\u003e\n\u003cli\u003eThe company received feedback from the FDA on pre-submissions to support 510(k) clearance of respiratory and CT\/NG\/TV test panels as of May 2023.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516265422997,"sku":"tlis-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/tlis-vrio-analysis.png?v=1740220019","url":"https:\/\/dcf-model.com\/es\/products\/tlis-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}